Every cycle has that one moment that splits winners from watchers. That’s the moment a project stops being “one to monitor” and becomes the one people wish ...

The IPO class of 2026 is likely to receive its first incumbent, after Aktis Oncology set its sights on a public listing that could see proceeds of around $210m. The cancer treatment-focused biotech ...

Initial public offerings are back in fashion, and the temptation is to treat every debut like a lottery ticket. In a market that rewards speed and narrative, the investors who actually keep their ...